|Articles|February 11, 2016
Canadian Drug Developer To Use OmniComm’s EDC
OmniComm’s TrialMaster EDC suite will be used for the collection of clinical data during a five year term in global Phase I to Phase III clinical studies.
Advertisement
OmniComm Systems, a leading provider of clinical data management technology, announced the signing of a five-year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How Sponsors Can Modernize Tools to Support PhysiciansSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
